How Much Does Retatrutide Cost in South Carolina in 2026?

Why Retatrutide Has No Retail Price in South Carolina Yet

Retatrutide does not have a set retail cost in South Carolina because the FDA has not approved it. The drug remains in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. No pharmacy in the state stocks a branded commercial product.

This matters for South Carolina residents searching for pricing information. Unlike semaglutide (Wegovy) or tirzepatide (Zepbound), which carry list prices above $1,000 per month, retatrutide has no manufacturer-set wholesale acquisition cost. The $0 figures circulating online reflect this investigational status, not a free drug. Once the FDA grants approval (analysts project late 2026 or 2027), Eli Lilly will announce pricing. Based on the company's tirzepatide (Mounjaro/Zepbound) pricing strategy, expect a branded list price between $900 and $1,200 per month before insurance, though the actual figure could differ 1.

South Carolina's 5.3 million residents include roughly 1.8 million adults with obesity (BMI ≥30), according to CDC prevalence data 2. Demand for a triple-agonist weight loss medication will be significant once commercial launch occurs. Until then, the only pathway to retatrutide in the state is through compounding pharmacies or clinical trial enrollment.

What Makes Retatrutide Different from Other GLP-1 Drugs

Retatrutide is the first triple-agonist peptide to reach late-stage clinical trials. It activates three receptors simultaneously: GIP, GLP-1, and glucagon. That third target, glucagon, sets it apart from every approved competitor.

Tirzepatide (Mounjaro/Zepbound) hits two of these three receptors (GIP and GLP-1). Semaglutide (Wegovy/Ozempic) activates only GLP-1. The addition of glucagon receptor agonism increases energy expenditure and hepatic lipid oxidation, meaning the body burns more calories at rest and clears liver fat more aggressively 3.

In the Phase 2 trial published in the New England Journal of Medicine by Jastreboff et al. (2023), 338 participants with obesity received retatrutide at varying doses for 48 weeks. Results were striking. The highest dose group (12 mg) achieved 24.2% mean body weight loss from baseline. By comparison, the SURMOUNT-1 trial of tirzepatide showed 22.5% weight loss at 72 weeks with the 15 mg dose 4. Retatrutide reached a comparable magnitude of loss in fewer weeks at a lower relative dose.

The Phase 2 data also showed that 100% of participants on the 12 mg dose lost at least 5% of their body weight, and 83% lost at least 15% 3. No approved obesity medication has matched those response rates in a controlled trial. Safety signals were consistent with the GLP-1 class: nausea (in up to 35% of participants at 12 mg), diarrhea, and constipation.

South Carolina Medicaid and Retatrutide

South Carolina Medicaid does not cover retatrutide. This is straightforward. The state cannot add an unapproved drug to its formulary.

Even after FDA approval, coverage is not guaranteed. South Carolina has historically excluded anti-obesity medications from its Medicaid preferred drug list. The state's Medicaid program, administered through managed care organizations like Healthy Blue and Select Health, does not currently cover Wegovy or Zepbound for weight management either 5. This reflects a broader national pattern: as of early 2026, only 15 state Medicaid programs cover any GLP-1 receptor agonist for obesity 6.

The Treat and Reduce Obesity Act, reintroduced in Congress, would require Medicare Part D to cover FDA-approved anti-obesity medications. If passed, it could pressure state Medicaid programs to follow. South Carolina legislators have not introduced state-level legislation mandating obesity drug coverage as of May 2026.

For South Carolina Medicaid beneficiaries with type 2 diabetes, a separate pathway may open. If Eli Lilly pursues a glycemic control indication for retatrutide (as it did with tirzepatide under the Mounjaro brand), Medicaid would likely cover it under the diabetes formulary, not the obesity formulary. Phase 2 data showed retatrutide reduced HbA1c by 2.02 percentage points at the 12 mg dose in participants with type 2 diabetes 7.

Private Insurance Coverage Outlook in South Carolina

No private insurer in South Carolina covers retatrutide because it is not an approved medication. Formulary decisions will begin only after the FDA issues an approval letter and Eli Lilly sets a wholesale acquisition cost.

Here is what to expect based on how South Carolina insurers handled tirzepatide and semaglutide. BlueCross BlueShield of South Carolina, the state's largest commercial insurer, added Zepbound to its formulary in 2024 with prior authorization requirements: a documented BMI ≥30 (or ≥27 with a weight-related comorbidity), failure of lifestyle modification, and prescriber attestation 8. Cigna and Aetna plans sold in South Carolina have similar step-therapy requirements for GLP-1 obesity drugs.

Retatrutide will almost certainly face the same prior authorization barriers. Typical out-of-pocket costs for South Carolina residents with commercial insurance who gain coverage of a branded GLP-1 range from $25 to $150 per month with a manufacturer copay card, or $250 to $500 per month without one, depending on plan design and deductible status.

Self-funded employer plans (covering roughly 60% of commercially insured South Carolinians) make independent formulary decisions. Large employers like BMW Manufacturing in Spartanburg, Prisma Health, and MUSC Health have increasingly added obesity pharmacotherapy to their benefit designs. A self-funded plan could choose to cover retatrutide from the first month of commercial availability.

Compounded Retatrutide in South Carolina: Legal Status and Pricing

Compounded retatrutide is available in South Carolina through 503A compounding pharmacies. This is legal under federal law as long as the pharmacy holds a valid state license and compounds from bulk drug substance for individual patient prescriptions.

A critical distinction. 503A pharmacies compound patient-specific prescriptions. 503B outsourcing facilities compound in bulk without individual prescriptions. Both pathways can legally produce retatrutide preparations because the drug's active ingredient is not on the FDA's "difficult to compound" list and is available as a research-grade peptide 9.

Pricing for compounded retatrutide in South Carolina varies widely. Expect $200 to $500 per month depending on the compounding pharmacy, dose, and whether the preparation is lyophilized (freeze-dried) or pre-mixed. This is significantly less than the anticipated branded price but comes with trade-offs. Compounded peptides are not FDA-approved, do not carry standardized bioequivalence data, and quality depends entirely on the compounding pharmacy's manufacturing controls.

South Carolina's Board of Pharmacy oversees 503A compounding within the state. The board requires pharmacies to follow USP <797> sterile compounding standards. Patients should verify that any pharmacy they use holds a current SC Board of Pharmacy license and complies with sterile compounding requirements. Ask for a certificate of analysis (COA) showing purity and potency testing by a third-party lab.

One caveat for the future: once the FDA approves branded retatrutide, 503A pharmacies will likely face restrictions on compounding it unless the drug enters shortage. This is what happened with tirzepatide. The FDA added tirzepatide to its drug shortage list in 2023, permitting compounding, then removed it in late 2024, triggering legal disputes over whether compounders could continue production 10.

Telehealth Access to Retatrutide in South Carolina

South Carolina permits telehealth prescribing of retatrutide. The state's Telemedicine Act, updated in 2023, allows licensed prescribers to establish a patient-provider relationship via audio-video technology and issue prescriptions for controlled and non-controlled substances.

Retatrutide is not a controlled substance. Any physician, nurse practitioner, or physician assistant licensed in South Carolina (or holding a valid multistate license) can prescribe it via telehealth after an appropriate clinical evaluation. The DEA's requirement for an in-person visit before prescribing controlled substances does not apply here.

Several national telehealth platforms already offer retatrutide consultations for South Carolina residents, typically connected to 503A compounding pharmacy fulfillment. Consultation fees range from $50 to $150 for an initial visit. Some platforms bundle the consultation fee into the monthly medication cost.

Telehealth is particularly relevant for rural South Carolina. Eighteen of the state's 46 counties are classified as medically underserved by HRSA 11. Residents of McCormick, Allendale, or Bamberg counties may have no local endocrinologist or obesity medicine specialist. Telehealth eliminates that geographic barrier entirely.

Manufacturer Savings Programs: What Eli Lilly Will Likely Offer

Eli Lilly has not announced a savings card or patient assistance program for retatrutide because the drug is not yet approved. But the company's track record with tirzepatide provides a reliable template.

When Lilly launched Zepbound in late 2023, it offered a savings card reducing out-of-pocket costs to $25 per month for commercially insured patients. The company also created the Zepbound Direct program in 2024, selling single-dose vials at $399 per month ($549 for the higher dose) directly to patients without insurance coverage 12. Lilly's LillyDirect platform handles fulfillment through partner pharmacies.

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine and investigator in obesity pharmacotherapy trials, has noted: "Eli Lilly has been more aggressive than any other manufacturer in creating direct-to-patient pricing pathways. Their strategy with Zepbound suggests they will replicate or expand these programs for retatrutide" 3.

South Carolina residents should watch for these programs to launch within weeks of FDA approval. Eligibility typically requires commercial insurance (not Medicare, Medicaid, or Tricare) and a valid prescription. Patients paying cash without insurance are usually eligible for the direct-purchase program but not the copay savings card.

How to Prepare Now If You Live in South Carolina

South Carolina residents interested in retatrutide can take concrete steps today rather than waiting passively for FDA approval.

First, establish care with a prescriber experienced in obesity pharmacotherapy. The Obesity Medicine Association's provider directory lists 47 board-certified obesity medicine specialists practicing in South Carolina 13. Greenville, Charleston, and Columbia have the highest concentration. Building a relationship now means you can get a prescription quickly once the drug becomes available.

Second, check your insurance formulary for existing GLP-1 coverage. If your plan covers Zepbound or Wegovy, it is more likely to add retatrutide after approval. Call the number on the back of your insurance card and ask your plan's pharmacy benefits manager whether they intend to cover new obesity medications in 2026 or 2027.

Third, if you are considering compounded retatrutide now, verify the pharmacy's credentials. The South Carolina Board of Pharmacy maintains a public license lookup. Confirm the pharmacy compounds under USP <797> standards and can provide third-party COA documents for every batch.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that clinicians "consider patient preferences, cost, insurance coverage, and access when selecting among available anti-obesity medications" 14. That guidance applies directly to the retatrutide decision. The "best" obesity drug is the one a patient can actually afford and access consistently.

Phase 3 Trial Data South Carolina Residents Should Know

The TRIUMPH clinical trial program includes four Phase 3 studies evaluating retatrutide for obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD, formerly NAFLD). Results from TRIUMPH-1 and TRIUMPH-2 are expected in late 2026.

Phase 2 results provide the strongest available evidence. In Jastreboff et al. (N=338), participants randomized to retatrutide 12 mg weekly lost a mean of 24.2% of body weight at 48 weeks, compared to 2.1% in the placebo group (P<0.001) 3. Weight loss had not plateaued at week 48, suggesting that longer treatment could produce even greater reductions.

The liver fat sub-study was equally notable. Among participants with baseline hepatic steatosis (liver fat ≥10% by MRI-PDFF), 86% of those on retatrutide 12 mg achieved complete resolution of liver fat (below 5%) at 48 weeks 15. No other anti-obesity medication has demonstrated that level of liver fat clearance. For South Carolina, where MASLD prevalence parallels national estimates of 30 to 38% of adults, this secondary benefit is clinically significant 16.

Dr. Ania Jastreboff, associate professor of medicine at Yale School of Medicine and lead investigator of the Phase 2 trial, stated: "The triple agonist mechanism of retatrutide addresses multiple metabolic pathways simultaneously, which may explain the magnitude of weight loss and metabolic improvements observed" 3.

South Carolina residents enrolled in the TRIUMPH trials through sites at MUSC or Prisma Health should continue follow-up as directed by trial investigators. Switching from a clinical trial to commercial or compounded product without consulting the study team could compromise both the participant's care and trial integrity.